Biomx Inc (PHGE) - Total Assets
Based on the latest financial reports, Biomx Inc (PHGE) holds total assets worth $26.17 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Biomx Inc to assess how comfortably operating cash covers total debt obligations.
Biomx Inc - Total Assets Trend (2017–2024)
This chart illustrates how Biomx Inc's total assets have evolved over time, based on quarterly financial data. See what is Biomx Inc's book value for net asset value and shareholders' equity analysis.
Biomx Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Biomx Inc's total assets of $26.17 Million consist of 47.5% current assets and 52.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 41.2% |
| Accounts Receivable | $1.17 Million | 2.7% |
| Inventory | $-958.00K | -2.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $12.05 Million | 27.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Biomx Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Biomx Inc (PHGE) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomx Inc's current assets represent 47.5% of total assets in 2024, a decrease from 60.6% in 2017.
- Cash Position: Cash and equivalents constituted 41.2% of total assets in 2024, down from 50.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 27.9% of total assets.
Biomx Inc Competitors by Total Assets
Key competitors of Biomx Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Jinyu Bio-Technology Co Ltd
SHG:600201
|
China | CN¥6.54 Billion |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
USA | $104.69 Million |
Biomx Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 3.17 | 8.47 |
| Quick Ratio | 1.70 | 3.29 | 8.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.64 Million | $19.37 Million | $53.51 Million |
Biomx Inc - Advanced Valuation Insights
This section examines the relationship between Biomx Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 26.81 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 72.7% |
| Total Assets | $43.23 Million |
| Market Capitalization | $1.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biomx Inc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biomx Inc's assets grew by 72.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biomx Inc (2017–2024)
The table below shows the annual total assets of Biomx Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $43.23 Million | +72.73% |
| 2023-12-31 | $25.03 Million | -45.03% |
| 2022-12-31 | $45.53 Million | -41.62% |
| 2021-12-31 | $77.99 Million | +10.84% |
| 2020-12-31 | $70.36 Million | -23.62% |
| 2019-12-31 | $92.12 Million | +103.22% |
| 2018-12-31 | $45.33 Million | +224.02% |
| 2017-12-31 | $13.99 Million | -- |
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more